Leap Therapeutics is developing targeted and immuno-oncology therapeutics for patients with DKK1 expressing tumors. DKK1 is produced and secreted by cancer cells influencing several tumor pathways and nearby immune cells, with high tumor levels associated with poor survival in many cancer conditions. Leap’s lead program has been the development of DKN-01, an anti-DKK antibody that has been tested across three different tumor types and is well tolerated in monotherapy and combination. However, Leap also has preclinical antibody programs targeting Claudin 18.2/CD137 and GDF15.

Leap Therapeutics

Founded: 2016
Location: Cambridge, MA
Employee range: 11 - 50
Clinical stage: Clin2
Therapy area: Gastric cancer
Drug types: ONC
Lead product: DKN-01
Funding: $90M stock Sep 2021; $45M stock Jun 2020; $27M stock, Jan 2020

Drug notes:

About:

Jobs: